*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Analysts at US investment bank Citi said on Wednesday that while Royal Dutch Shell's (RDS) business update had excited the market with its view on how to improve free cash flow (FCF) yields, it was the life of the company's reserves that would tell the real story.
Software and services company Fidessa was under pressure on Wednesday as Stifel initiated coverage of the stock at 'sell' with a 2,054p price target, pointing to a number of headwinds.
Spire Healthcare got a shot in the arm on Wednesday as Berenberg upgraded its stance on the stock to 'buy' from 'hold' and lifted the price target to 310p from 270p on the back of new NHS data.
